haematology
IMPEDE-VTE Score for VTE Risk in Multiple Myeloma
Risk stratification tool for venous thromboembolism (VTE) in patients with multiple myeloma receiving immunomodulatory drug (IMiD) based therapy. Score guides choice of VTE prophylaxis: low risk = aspirin, high risk = anticoagulation (LMWH or DOACs). Developed by Li et al. 2020. Endorsed by IMWG VTE prophylaxis guidelines.
References
- Li A et al. IMPEDE VTE: A novel score that incorporates IMiD-based therapy to predict venous thromboembolism in multiple myeloma. Blood Adv. 2020;4(8):1594-1603.
- Palumbo A et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414-423.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Thalidomide · Immunomodulatory Drug (IMiD) — Myeloma
- Lenalidomide · Immunomodulatory Drug (IMiD)
- Thalidomide (Rheumatology / Dermatology) · Immunomodulatory Drug (IMiD)
- Lenalidomide (Specialist drug) · Immunomodulatory drug (IMiD)
- Pomalidomide (Specialist drug) · Immunomodulator (thalidomide analogue)
- Enoxaparin (LMWH) · Anticoagulant
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.